Status:
COMPLETED
Secondary Care - Continuous Glucose Monitoring
Lead Sponsor:
Croatian Society for Endocrinology and Diabology
Collaborating Sponsors:
Takeda
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
3-8 years
Brief Summary
Introduction and objective: The current state of glucose monitoring includes the use of A1C, self-monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM). CGM technology has got th...
Detailed Description
STUDY DESIGN: An observational, multicenter, cross-sectional study. A total of 20 diabetologist from four Croatian regions will recruit up to ten subjects of both sexes from May 2018 till the end of M...
Eligibility Criteria
Inclusion
- T2DM diagnosed at least one year prior to study entry
- Only basal insulin in therapy
- Patients' ability to understand and answer the questionnaire by themselves
- Signed informed consent
Exclusion
- Known coagulopathy
- Oral anticoagulants in therapy
- Skin disease that enables continuous glucose monitor device application
- Febrile illness
- Patient's inability to physically visit a general practitioners office
- Patient's inability to answer the questionnaire by themselves
Key Trial Info
Start Date :
March 19 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 25 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03487887
Start Date
March 19 2018
End Date
August 25 2021
Last Update
September 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Centre Zagreb
Zagreb, Croatia, 10 000